The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. [electronic resource]
Producer: 20160920Description: 2431-8 p. digitalISSN:- 1178-2005
- Administration, Inhalation
- Adrenal Cortex Hormones -- administration & dosage
- Adrenergic beta-2 Receptor Agonists -- administration & dosage
- Androstadienes -- administration & dosage
- Biomarkers -- blood
- Bronchodilator Agents -- administration & dosage
- Chemokines, CC -- blood
- Clinical Protocols
- Disease Progression
- Double-Blind Method
- Drug Combinations
- Ethanolamines -- administration & dosage
- Fluticasone
- Forced Expiratory Volume
- Formoterol Fumarate
- Humans
- Lung -- drug effects
- Pulmonary Disease, Chronic Obstructive -- blood
- Pulmonary Surfactant-Associated Protein D -- blood
- Recovery of Function
- Research Design
- Spirometry
- Surveys and Questionnaires
- Time Factors
- Treatment Outcome
- Vital Capacity
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.